Briteseed is a medical diagnostic imaging company developing SafeSnips, an intraoperative platform technology that integrates into existing surgical cutting tools to facilitate the real-time detection and imaging of hidden blood vessels before surgical cuts are made. Anchored in work undertaken at Accidental vessel injury is a significant problem for patients, surgeons, and costs U.S. hospitals more than $10B every year. Briteseed provides a low-cost, real-time, and unobtrusive technology for vessel detection to address this need. The Company's business model will focus on out-licensing their disposable sensor technology for a wide range of surgeries, while their market focus will be on thermal ligature devices, the most frequently used surgical cutting tools which comprise a $1.2B global market. Hospitals will be incentivized to purchase SafeSnips-enabled devices to improve surgical outcomes and to reduce non-reimbursable costs associated with accidental surgical cuts. The Company plans to commercialize their first product within two years, led by a well-qualified technical and business team and advisory board who consist of highly-regarded clinicians and scientists, serial entrepreneurs, and early-stage investors with significant medical device experience. Further development of the SafeSnips platform technology will extend to the real-time detection of other vessels and tissues during surgery.
